Circulating DF3 and CA125 antigen levels in serum from patients with epithelial ovarian carcinoma.
Circulating DF3 and CA125 antigen levels in serum from patients with epithelial ovarian carcinoma.
复制标题
上皮性卵巢癌患者血清中循环 DF3 和 CA125 抗原水平。
DOI：
10.1200/jco.1985.3.10.1355
复制
发表时间：
1985
期刊：
影响因子：
--
通讯作者：
Donald Kufe
中科院分区：
文献类型：
--
作者：
Hiroshi Sekine;Daniel F. Hayes;Tsuneya Ohno;Kristin A. Keefe;Elena Schaetzl;Robert C. Bast;R. Knapp;Donald Kufe
鼠单克隆抗体（MAb），命名为DF 3，与300千道尔顿（kd）乳腺上皮抗原反应。建立了一种双决定簇酶联免疫测定法（EIA），用于监测循环DF 3抗原。先前的研究已经证明，DF 3 EIA的使用提供了一种新的和潜在有用的标记物，以跟踪转移性乳腺癌患者的临床过程。在本研究中，我们监测了卵巢上皮性癌和非卵巢妇科恶性肿瘤患者血清中的循环DF 3抗原。45例卵巢癌患者中有21例（47%）DF 3抗原水平升高（大于或等于30 U/mL）。相反，20例非卵巢妇科恶性肿瘤患者中有3例（15%）循环DF 3抗原升高，59例对照妇女中只有4例（7%）循环DF 3抗原升高。卵巢癌患者和对照组的DF 3抗原值之间的差异是显著的（P小于0.001）。卵巢癌患者中循环DF 3抗原的升高也已通过transblot测定证实。MAb DF 3反应性主要发生在分子量（摩尔/重量）为300至450 kd的循环抗原。此外，DF 3抗原水平已被证明与6名卵巢癌患者的疾病进展和另外2名患者的疾病切除术后相关。循环DF 3抗原的半衰期约为45至60天。结果还表明，DF 3抗原与CA 125不同，CA 125是一种与体腔上皮和发育羊膜相关的糖蛋白。使用DF 3 EIA和免疫放射分析先前描述的检测循环CA 125表明，确定这两种标志物的水平可以提高监测卵巢癌过程的灵敏度。此外，这两种检测方法的使用可能有助于区分卵巢癌与其他恶性肿瘤。
The murine monoclonal antibody (MAb), designated DF3, reacts with a 300-kilodalton (kd) mammary epithelial antigen. A sequential double-determinant enzyme-linked immunoassay (EIA) has been developed to monitor circulating DF3 antigen. Previous studies have demonstrated that the use of the DF3 EIA provides a new and potentially useful marker to follow the clinical course of patients with metastatic breast cancer. In the present study, we have monitored circulating DF3 antigen in the serum of patients with epithelial ovarian carcinomas and non-ovarian gynecologic malignancies. Twenty-one of 45 patients (47%) with ovarian carcinoma had elevated DF3 antigen levels (greater than or equal to 30 U/mL). In contrast, three of 20 patients (15%) with non-ovarian gynecologic malignancies, and only four of 59 control women (7%) had elevation of circulating DF3 antigen. The difference between DF3 antigen values from patients with ovarian cancer and from controls was significant (P less than .001). The elevation of circulating DF3 antigen in ovarian cancer patients has also been confirmed by transblot assays. MAb DF3 reactivity occurred predominately with circulating antigens of molecular weights (mol wt) ranging from 300 to 450 kd. Furthermore, DF3 antigen levels have been shown to correlate with progression of disease in six patients with ovarian cancer and after resection of disease in two others. The half-life of circulating DF3 antigen was approximately 45 to 60 days. The results also demonstrate that DF3 antigen is distinct from CA125, a glycoprotein associated with coelomic epithelium and developmental amnion. The use of both the DF3 EIA and the immunoradiometric assay previously described to detect circulating CA125 suggests that determining levels of both markers may enhance the sensitivity of monitoring the course of ovarian cancer. Furthermore, the use of both assays may be useful in distinguishing ovarian cancer from other malignancies.
影响因子：
15.9
作者：
BAST, RC;FEENEY, M;KNAPP, RC
通讯作者：
KNAPP, RC